BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Cidara Therapeutics, Inc. (Nasdaq - CDTX), Mersana Therapeutics, Inc. (Nasdaq - MRSN), TreeHouse Fo...
Cidara Therapeutics, Inc. (CDTX)
Last cidara therapeutics, inc. earnings: 3/4 05:55 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cidara.com
Company Research
Source: GlobeNewswire
BALA CYNWYD, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you. Cidara Therapeutics, Inc. (Nasdaq - CDTX) Under the terms of the Merger Agreement, Cidara will be acquired by Merck (NYSE- MRK) for $221.50 per share in cash, for a total transaction value of approximately $9.2 billion. The investigation concerns whether the Cidara Therapeutics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company’s shareholders. Additional information can be found at https://www.brodskysmith.com/cases/cidara-therapeutics-inc-nasdaq-cdtx/. Mersana Therapeutics, Inc. (Nasdaq - MRSN) Under the terms of the agreement, Mers
Show less
Read more
Impact Snapshot
Event Time:
CDTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CDTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CDTX alerts
High impacting Cidara Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CDTX
News
- Halper Sadeh LLC Encourages GIFI, MOVE, RMBI, CDTX Shareholders to Contact the Firm to Discuss Their RightsPR Newswire
- Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk PopulationsGlobeNewswire
- SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-NUVSF, NDTAF, THS, and CDTXPR Newswire
- Big Pharma Has Spent Nearly $150 Billion On M&A (So Far) In 2025 [Forbes]Forbes
- Cidara Therapeutics (NASDAQ:CDTX) had its "neutral" rating reaffirmed by analysts at Guggenheim.MarketBeat
CDTX
Earnings
- 11/6/25 - Miss
CDTX
Sec Filings
- 12/5/25 - Form SC
- 12/5/25 - Form SC
- 11/17/25 - Form SCHEDULE
- CDTX's page on the SEC website